NCT00406783

Study for the Treatment of Intermittent Allergic Rhinitis With Desloratadine (Study P04683)

Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter/Multinational, Efficacy and Safety Study of Desloratadine 5 mg in the Treatment of Subjects With Allergic Rhinitis Who Meet the Criteria for Intermittent Allergic Rhinitis (IAR)

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 547 (actual)
• Sponsor: Organon and Co · Industry
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

This study will investigate the effectiveness of desloratadine in treating subjects with allergic rhinitis (AR) who meet the criteria for intermittent allergic rhinitis.

Conditions

• Rhinitis, Allergic, Seasonal
• Rhinitis, Allergic, Perennial

Interventions

Type	Name	Description
DRUG	5-mg Desloratadine	5-mg Desloratadine tablet, once daily for 15 days
DRUG	Placebo	Placebo tablet, once daily for 15 days

Timeline

• Start date: 2006-08-01
• Primary completion: 2007-11-01
• Completion: 2007-11-01
• First posted: 2006-12-04
• Last updated: 2024-05-20
• Results posted: 2009-03-06